Global Bone Growth Stimulator Market: Key Developments
In May 2022, Orthofix Medical Inc., a medical device company with a spine and orthopedics focus announced the U.S. Food and Drug Administration (FDA) pre-market approval for the AccelStim bone healing therapy Class III device. The device generates a Low-Intensity Pulsed Ultrasound (LIPUS) signal to stimulate the bone’s natural healing process to promote fracture healing. Commercial availability of the AccelStim device is anticipated to occur in the second quarter of 2022 year through a targeted and phased launch plan.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients